secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001753926-24-000612
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical shifts focus to GLP-1 obesity implants; Q4 net loss $6.0M
------------------------------------------------------------------------

- Cash and equivalents $22.0M as of Dec 31, 2023, down from $46.4M; $15M March 2024 financing extends runway into H2 2025.
- Full-year 2023 net loss $25.7M vs $13.9M in 2022; R&D expenses rose 20% to $17.0M.
- Positive preclinical data: NPM-115 (exenatide) showed ~20% weight loss in obese mice, comparable to semaglutide.
- Daniel Bradbury appointed to Board; led Amylin's approval of once-weekly GLP-1 Bydureon.
- Anticipates NPM-115 IND filing in H2 2024 and NPM-119 clinical hold response in H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624000612/0001753926-24-000612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624000612/g084147_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-000612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer